MedTrace Logo

Multiple Dose Study To Investigate The Effects Of Fesoterodine And Solifenacin On Gastrointestinal Transit

NCT00832650 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2010-12-24

Study results available
· View outcomes & findings →

Summary

To assess the effect of fesoterodine 8 mg as compared to solifenacin 10 mg on colonic transit.

Conditions

  • Healthy

Interventions

DRUG

fesoterodine fumarate

8 mg OD for 14 days

DRUG

placebo

OD for 14 days

DRUG

solifenacin

10 mg OD for 14 days

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00832650 on ClinicalTrials.gov